Nektar and Puretech make strange bedfellows

If you are wondering what the logic is behind merging an inhaled drug delivery specialist that turned to oncology with a holding company that has a portfolio of disparate healthcare assets you are probably not alone. This morning’s market reaction suggests that investors, too, are puzzled by Nektar’s preliminary approach, confirmed today, to Puretech Health.